GYRE THERAPEUTICS INC (GYRE) — insider trading
Health Care · NASDAQ
GYRE THERAPEUTICS INC (GYRE) has 32 reported SEC Form 4 insider transactions in our data, including 8 open-market sales among the most recent 32 (latest 2026-06-18).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 3,000 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 3,000 | $6.35 | $19.1K | Form 4 |
| 2026-06-18 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 3,000 | $0.75 | $2.3K | Form 4 |
| 2026-06-11 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 2,800 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 2,800 | $6.17 | $17.3K | Form 4 |
| 2026-06-11 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 2,800 | $0.75 | $2.1K | Form 4 |
| 2026-06-10 | Nussbaum Rodney L | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-10 | Zhang Ping | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-10 | Parry Renate | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-10 | Weng Dan | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-10 | Epstein David M. | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-10 | Carmichael Gordon | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-10 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 5,000 | $0.00 | $0 | Form 4 |
| 2026-06-10 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 5,000 | $6.24 | $31.2K | Form 4 |
| 2026-06-10 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 5,000 | $0.75 | $3.8K | Form 4 |
| 2026-06-10 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 6,418 | $0.00 | $0 | Form 4 |
| 2026-06-10 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 6,418 | $6.21 | $39.9K | Form 4 |
| 2026-06-10 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 6,418 | $0.75 | $4.8K | Form 4 |
| 2026-06-09 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 3,000 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 3,000 | $6.15 | $18.4K | Form 4 |
| 2026-06-09 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 3,000 | $0.75 | $2.3K | Form 4 |
| 2026-06-09 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 14,500 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 14,500 | $6.14 | $89.0K | Form 4 |
| 2026-06-09 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 14,500 | $0.75 | $10.9K | Form 4 |
| 2026-06-08 | Luo Ying | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 120,000 | $0.00 | $0 | Form 4 |
| 2026-06-08 | Bergmann Joshua Benjamin | Officer (GC and Corporate Secretary) | Grant / award / vesting (derivative) | 50,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 15,401 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 15,401 | $6.40 | $98.6K | Form 4 |
| 2026-06-05 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 15,401 | $0.75 | $11.6K | Form 4 |
| 2026-06-04 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 19,575 | $0.00 | $0 | Form 4 |
| 2026-06-04 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 19,575 | $6.13 | $120.0K | Form 4 |
| 2026-06-04 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 19,575 | $0.75 | $14.7K | Form 4 |
Ask the chat about GYRE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: GYRE THERAPEUTICS INC (GYRE).
Last updated 2026-06-18 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.